Xenon Pharmaceuticals XENE Unrealized Gain (Loss), Foreign Currency Transaction, before Tax
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossUnrealized.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax?
- Xenon Pharmaceuticals (XENE) reported unrealized gain (loss), foreign currency transaction, before tax of $204K in Q1 2026.
- How has Xenon Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax changed year-over-year?
- Xenon Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax increased by 212.1% year-over-year, from -$182K to $204K.
- What does unrealized gain (loss), foreign currency transaction, before tax mean?
- This metric represents the non-cash impact of fluctuations in foreign exchange rates on monetary assets and liabilities denominated in currencies other than the company's functional currency. It reflects unrealized gains or losses that have not yet been settled through actual cash transactions. Monitoring this helps investors understand the company's exposure to currency volatility in its international operations.